The Biostatistics Core is a Shared Resource organized to meet the diverse statistical needs of USC Norris investigators. The Core is led by two very experienced, biostatistical experts in clinical and translational study design and analysis, Dr. Susan Groshen (Core Director) and Dr. Richard Sposto (Core Co-Director). The Core also comprises faculty members of the prominent Division of Biostatistics in the Department of Preventive Medicine at the USC Keck School of Medicine ? Drs. James Gauderman, Kimberly Siegmund, Joshua Millstein, and Chih-Ping Chou ? who represent complementary expertise in statistical design and analysis methods in population science, cancer prevention and control, genetic epidemiology, and epigenetics. These faculty, along with a well-trained and well-mentored staff of six PhD and MS statisticians and two technical experts in clinical database design, make the Core extremely effective in collaborating with investigators in all Cancer Center programs to design laboratory, clinical, and population studies, carry out complex statistical analyses, author and co-author scientific papers, ensure the proper conduct of clinical trials and the integrity of the data collected, develop statistical designs and analytic plans in support of applications for extramural funding, and serve as co-investigators on research grants. During the project period, Core members have worked with 118 USC Norris Cancer Center members on 823 cancer-related projects, resulting in a substantive contribution to 74 awarded grants for research funding that total $38M in direct costs ($55M total costs) in support of Cancer Center research over the last project period. Core members co-authored or authored 214 cancer-related publications. They have also actively participated in the Clinical Investigation Committee (PRMS), Data and Safety Monitoring Committee (DSMC), Quality Assurance Committee (QAC), and Study Progress and Monitoring (SPAM) Subcommittee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-44
Application #
9607932
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications